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Abstract 
 
Background: Pulmonary hypertension (PH) is a fatal disease characterized by pulmonary artery 
(PA) remodeling, elevated PA pressure and right ventricular (RV) failure.  It was previously 
demonstrated that treatment with a Rho-kinase inhibitor, fasudil, ameliorates PH in animal 
models.  Here, I examined whether combination therapy with fasudil and sildenafil further 
ameliorates PH in rats.  Methods and Results: PH was induced in Sprague-Dawley rats by a 
single subcutaneous monocrotaline (MCT) injection, which caused PA remodeling, elevated RV 
systolic pressure (RVSP), and RV hypertrophy (RVH).  While fasudil and sildenafil 
monotherapy ameliorated the development of MCT-induced PH in the prevention and treatment 
protocols, their combination therapy further improved RVSP and RVH.  Moreover, histological 
examination demonstrated significant improvements of PA remodeling in the combination group 
compared with the monotherapy groups.  Echocardiographic examination also revealed 
significant reduction in RV diameter in the combination group compared with the monotherapy 
groups.  Mechanistic experiments revealed significant inhibition of Rho-kinase activity in PA 
trunk, lung and RV tissues in the combination group as well as in the monotherapy groups.  
Finally, the combination therapy markedly improved the long-term survival compared with the 
monotherapy groups.  Conclusions: These results indicate that the combination therapy with 
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fasudil and sildenafil shows the synergistic effects through inhibition of Rho-kinase activity for 
the treatment of PH. 
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Introduction 
 
Pulmonary arterial hypertension (PAH) is an intensifying fatal disease, characterized by an 
increased pulmonary vascular resistance, abnormal sustained pulmonary vasoconstriction, and 
progressive structural remodeling of pulmonary arteries, that precedes to right ventricular (RV) 
failure and premature death.1-3)  Usually the PAH patients meet specific hemodynamic criteria 
including a mean pulmonary arterial pressure >25 mm Hg, pulmonary capillary wedge or left 
ventricular end-diastolic pressure <15 mm Hg, and pulmonary vascular resistance >3 Wood 
units.4-6)  The global prevalence of PAH is very difficult to estimate due to lack of access to care 
and accurate diagnosis in many countries.  However, some study reported that the incidence of 
PAH is estimated about 2̴8 cases/million annually, whereas the prevalence of PAH is 15̴26 
cases/million annually.7, 8)  Although the past decade has witnessed an unsurpassed interest and 
progress in the molecular understanding of PAH and the development of new treatment strategies, 
the prognosis for patients with the disease remains poor with a median survival of 2.8 years.9)  
Significant morbidity and mortality continue to dominate despite the modern management of 
PAH and the survival falls as low as 54.9% at 3 years after the diagnosis.9)  The key underlying 
reason for this may be the complexity of PAH involving a multitude of redundant pathways, 
which are further influenced by many overlapping secondary messenger systems.   
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The pathogenesis of PAH is a complex and multifactorial process which includes 
endothelial dysfunction, vascular smooth muscle cells (VSMC) proliferation & hypercontraction, 
and inflammatory cell migration (Figure 1A).6, 10-12)  Further understanding of the molecular 
and genetic mechanisms of PAH have introduced the concept of multiple-hit hypothesis, which 
states that the disease is initiated as a result of interaction of a predisposing state and one or more 
stimuli.13, 14)  The hits may consist of a genetic abnormality or substrate being combined with a 
systemic disorder (ie, collagen vascular disease, human immunodeficiency virus), an 
environmental trigger (ie, hypoxia, anorexigens) or additional genetic conditions (ie, mutation, 
polymorphism).   This may result an imbalance of mediators such as endothelin-1, angiotensin 
II that culminates in pulmonary arterial vasculopathy.  The current treatment approach of PAH is 
based on targeting the aberrancies identified in 3 main biologic pathways as endothelin, nitric 
oxide and prostacyclin pathways (Figure 1B).1)  Therefore, we obtained new therapeutic options 
such as prostanoid analogues, endothelin receptor blockers, and phosphodiesterase type 5 (PDE5) 
inhibitors.5)  However, no single agent has been shown to provide entirely satisfactory results.  
Recently, it has been proposed that combination therapy may provide additive benefits by 
simultaneously addressing several disease pathways.15)  Moreover, certain combinations may 
also show synergistic benefits, beyond a simple additive effect, by inhibiting multiple signaling 
pathways.15)  It was also notified that approximately 43% PAH patients need combination 
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therapy with two drugs to achieve the desired clinical stability.16)  There are many combination 
therapeutic approaches already been reported and showed great promises in clinical trials and 
animal studies. 17-24)  However, there is no direct evidence as to the beneficial combination that 
will improve the long-term survival in PAH.16)  So, it is required to target as many pathways as 
possible for the PAH treatment.  
Recent advances in molecular biology have elucidated the substantial involvement of 
intracellular signaling pathways mediated by small GTP-binding proteins (G proteins) such as 
Rho.25-27)  Rho-kinase, a downstream molecule of Rho, is involved in various cellular functions, 
including VSMC contraction, actin cytoskeleton organization, cell adhesion and motility, 
cytokinesis and gene expressions.28-33)  Additionally, Rho-kinase causes VSMC proliferation, 
vascular contraction and remodeling by multiple mechanisms (Figure 2A).34, 35)  We have 
previously demonstrated that Rho-kinase is substantially involved in the pathogenesis of 
pulmonary hypertension (PH) in animal models.36-38)  Indeed, Rho-kinase is an important 
therapeutic target in cardiovascular diseases29) and Rho-kinase inhibition ameliorates PH in 
animals and humans.38-41)  Pulmonary vascular remodeling is an important pathogenesis of PH, 
in which another signaling pathway through the nitric oxide (NO) and cGMP is involved.42, 43)  
Pulmonary vascular cGMP levels are increased by inhibiting the phosphodiesterases (PDEs) that 
are responsible for cGMP hydrolysis in the pulmonary vasculature (Figure 2B).42, 44)  So, PDE5 
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inhibition will cause relatively selective pulmonary vasodilatation with less effect on systemic 
pressure.42) 
In molecular level of PAH, most of the pathologic changes occurred by vasoconstriction 
in Ca+2 dependent and Ca+2 independent pathway.45)  Different studies in rodents and humans 
suggested that Rho-kinase mediates the Ca+2 sensitization process and plays an important role in 
the regulation of vasoconstriction in pulmonary arterial hypertension.45)  Rho-kinase inhibitor 
decrease Ca+2 sensitization through the inhibition of myosin phosphatase phosphorylation.46)  
Another study also showed that sildenafil also inhibited Ca+2 sensitization of the contraction in 
arterial smooth muscle contraction.47)     
Previously it was published from our group that combination therapy with fasudil and 
prostacyclin ameliorated monocrotaline-induced PH.20)  Importantly, recent study demonstrated 
that sildenafil, a PDE5 inhibitor, inhibits Rho-kinase activity in an animal model of PH.48)  So, 
there is a chance of getting synergistic interaction between Rho-kinase inhibitor, fasudil and a 
PDE5 inhibitor, sildenafil.  Therefore, I hypothesized that the combination therapy with fasudil 
and sildenafil could further ameliorate PH by their additive and synergistic interaction between 
Rho-kinase and NO/cGMP/PDE5 signaling.   
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Aim of the Study 
 
Because of the additive and synergistic interaction between Rho-kinase inhibitor, fasudil and 
PDE5 inhibitor sildenafil, I hypothesized that combination therapy with fasudil and sildenafil 
would be more effective compared to monotherapy with fasudil or sildenafil in treating PAH.   
In the present study, I thus tested our hypotheses that (1) the combination therapy with fasudil 
and sildenafil further ameliorates monocrotaline-induced PH compared to monotherapy with 
fasudil or sildenafil in rats & (2) the combination therapy with fasudil and sildenafil also 
improves right ventricular function and long-term survival in monocrotaline-induced PH in rats. 
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Materials and Methods 
 
Animals 
Adult male Sprague-Dawley rats (6 weeks of age, 150~170g body weight) were purchased from 
SEIMI Corporation (Sendai, Japan).  All procedures were performed according to the protocols 
approved by the Institutional Committee for Use and Care of Laboratory Animals of Tohoku 
University.  Animals were housed under climate controlled conditions on a 12:12-hour 
light-dark cycle with access to chow and water.  They were allowed 1 week to adjust to the new 
environment prior to the experiment.   
 
Monocrotaline 
Monocrotaline (MCT, Sigma-Aldrich Co, St. Louis, MO, USA) was dissolved in 1N HCl, and the 
pH was adjusted to 7.4 with 1N NaOH.20, 38)  The solution was administered as a single 
subcutaneous (SC) injection (60 mg/kg) in a volume of 3 ml/kg.  Control, age-matched rats 
received an equal volume of isotonic saline.20, 38) 
 
Experimental Protocols 
A total of 203 male rats (7 weeks of age) were used for the present study, for hemodynamic 
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measurements, morphometric analysis and echocardiographic measurement in the prevention and 
treatment protocols.  All rats were given a subcutaneous injection of either monocrotaline (60 
mg/kg) or 0.9% saline, where MCT induced severe PH in 3 weeks.38)  In the prevention protocol, 
animals were orally treated with vehicle, fasudil (30 mg/kg/day), sildenafil (10 mg/kg/day), or 
both of them for 3 weeks concomitantly with MCT injection.38)  In the treatment protocol, 
animals were orally treated with the same drugs or vehicle, starting at day 21 after MCT 
administration when severe PH had already been established.38)  Fasudil and sildenafil were 
provided by Asahi Kasei Pharma Co (Shizuoka, Japan) and Pfizer (Groton, CT, USA), 
respectively.  The doses of fasudil and sildenafil were selected based on the previous studies 
from our laboratory and others.  It was found that that the Rho-kinase inhibitor, fasudil (30 and 
100mg/kg/day) showed dose-dependent action in pulmonary hypertension.38)  However, I chose 
the lower dose of fasudil as 30 mg/kg/day to be closer to clinical dose.   Similarly, another 
study described the dose dependent action of PDE5 inhibitor, sildenafil (0, 3, 10, 30 or 100 
mg/kg/day) in PH.17)  Here, I also chose the lower dose of sildenafil as 10 mg/kg/day for the 
same reason.  This protocol resulted in the creation of 5 groups: control group (saline SC and 
vehicle orally), MCT group (MCT SC and vehicle orally), FAS group (MCT SC and fasudil 
orally), SIL group (MCT SC and sildenafil orally) and FAS+SIL group (MCT SC and 
combination with fasudil and sildenafil orally).  Hemodynamic, echocardiographic, histologic 
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and Western blot analyses were performed 3 weeks after MCT injection in the prevention 
protocol and 9 weeks after MCT injection in the treatment protocol.38)  Water and food intake 
were measured every week.   
 
Hemodynamic Measurements 
Hemodynamic measurements were performed by using a Millar Mikrotip® catheter (SPR 320, 
size 2F, Millar Instruments, Houston, Texas, USA),49) transducer and the PowerLab data 
acquisition system (AD Instruments, Sydney, Australia) connected to a polygraph system (AB 
601G, Nihon Kohden, Tokyo, Japan).  All animals were anesthetized with inhaled isoflurane by 
an anesthesia unit, Univentor 400 (Univentor High Precision Instrument, Zejtun ZTN, Malta) and 
placed on a heating pad to maintain body temperature in the physiological range (37oC) 
throughout the study.  RV systolic pressure (RVSP) was measured by insertion of Milllar 
catheter into the right jugular vein, then through the right atrium into the RV.  Systolic arterial 
pressure (SAP) was also measured by the catheter inserted into the left carotid artery.  
 
Right Ventricular Hypertrophy 
The heart was excised after sacrificing the animal.  The RV was dissected from the left ventricle 
(LV) and septum (S).  These samples were weighted to determine the extent of RV hypertrophy 
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(RVH) as RV/(LV+S) ratio and also in terms of body weight (BW) as RV/BW.38, 50) 
 
Morphometric Analysis  
After the hemodynamic measurement, the lungs were perfused with physiological salt solution 
and were fixed with 10% formalin for morphometric analysis.  Paraffin sections (5 μm) were 
obtained from the left lung and stained with Elastica Masson for examinations by light 
microscopy (BZ-9000, KEYENCE, Elmwood Park, NJ, USA).  The measurement of medial 
thickness was assessed in pulmonary arteries with an external diameter of 50~200 μm.  The 
pulmonary arteries were divided into 2 groups (50~100 and 100~200 μm in diameter) for analysis.  
Medial thickness was expressed as follows; percent wall thickness = [(medial thickness x 
2)/external diameter] x 100.38)  More than 20 pulmonary arteries per animal were measured. 
 
Echocardiographic Measurements 
Echocardiographic measurements were performed after 3 weeks of MCT injection.  Rats were 
anesthetized using inhaled isoflurane and placed in supine position.  After shaving the chest, a 
depilatory cream (Nair, Canada) was applied.  The ultrasound transmission gel was kept in the 
thermasonic gel warmer at 37oC.  Two-dimensions (2D) and M-mode images were recorded by 
the Toshiba echocardiographic system (SSA-770A, Toshiba Corporation, Tokyo, Japan) through 
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the right parasternal long axis view of the heart.51)  M-mode (motion mode) images were used to 
determine RV end-systolic diameter (RVESD) and RV end-diastolic diameter (RVEDD) as 
measures for RV dilatation.  RV fractional shortening (RVFS) was also determined as measures 
for RV contractility.24)   
 
Western Blot Analysis 
Pulmonary arteries (PA), lungs and RV tissues (100 mg each) were homogenized individually 
with 1 ml of 10% TCA (trichloroacetic acid) buffer with autohomogenizer (Precellys 24, Bertin 
Technologies, France) and centrifuged.  Then, the cell lysate was washed with PBS (Phosphate 
buffered saline) and re-suspended in Urea/SDS buffer.  Protein concentration of the supernatant 
was determined by Pierce BCA protein assay kit (Thermo Scientific, IL, USA).  Equal amounts 
of protein were loaded in each lane of polyacrylamide/SDS gels (Mini Protean TGX Gels, 
BIO-RAD Laboratories Inc., CA, USA ), which were then electrophoresed and transferred to 
PVDF membrane (Amersham Hybond-P, GE Healthcare, UK).  Lysates were analyzed by 
Western blot.  Equal loading was confirmed by re-probing the membrane with monoclonal 
anti-α-tubulin antibody (Sigma-Aldrich Co, St. Louis, MO, USA) and anti- actin antibody 
(Abcam).  Rho-kinase activity was analyzed by Western blot analysis for MYPT (myosin 
phosphatase targeting subunit) using purified mouse anti-MYPT1 antibody (BD transduction 
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Laboratories, USA) and for phosphorylated MYPT1 using a rabbit polyclonal 
anti-phospho-MYPT1 (Thr696) antibody (Millipore, MA, USA).38)  ERK (extracellular-signal 
regulated kinases) activity was also analyzed by Western blot analysis for ERK1/2 protein using 
p44/42 MAPK (Erk1/2) antibody (Cell Signaling Technology, Danvers, MA 01923) and for 
phosphorylated ERK1/2 using a rabbit polyclonal phosphor-p44/42 MAPK 
(Erk1/2)(Thr202/Tyr204) Antibody (Cell Signaling Technology, Danvers, MA 01923).  Western 
blots were visualized using horseradish peroxidase-conjugated secondary antibody and 
subsequent ECL detection (GE Healthcare, UK) with LAS-4000 mini instrument (Fujifilm, 
Tokyo, Japan), then quantified by densitometric analysis using ImageJ software (NIH).       
 
Survival Study 
I conducted the survival study of monocrotaline injected rats to examine the effects of long term 
therapy with fasudil, sildenafil and the combination of these drugs.  I also wanted to learn 
whether the combination therapy has any beneficial effects on survival over the monotherapy 
with fasudil and sildenafil alone.  The survival study included the entire experimental period 
from the day 0 (the day of monocrotaline injection) to the day 63 (the finishing day of treatment 
with drugs). 
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Statistical Analysis 
All results are expressed as mean ± SEM.   The log-rank test was used to determine the P value 
for Kaplan-Meier survival curves.  Analyses were performed in SPSS, version 19.0 (Chicago, 
IL, USA) and R version 3.0.1.  Differences in all other parameters were evaluated by ANOVA 
followed by both Dunnett and Fisher’s post hoc test.  A value of P<0.05 was considered to be 
statistically significant.  
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Results 
 
Combination Therapy Improves Hemodynamic Variables  
Male Sprague-Dawley rats were injected with a single dose of monocrotaline to induce PH.  I 
measured hemodynamics at 3 weeks after MCT injection in the prevention protocol and at 9 
weeks after the injection in the treatment protocol (Figure 3).  Catheter examination revealed 
that RVSP was significantly elevated in the MCT group compared with the control group both in 
the prevention and treatment protocols (Figure 4A and 4B).  In the prevention protocol, the 
monotherapy with fasudil or sildenafil significantly reduced RVSP (by 24% and 35% 
respectively), and their combination therapy further reduced RVSP (by 45%) compared with each 
monotherapy (Figure 4A).  In the treatment protocol, the monotherapy with fasudil or sildenafil 
significantly reduced RVSP (by 20% and 29% respectively), which was further reduced by their 
combination therapy (by 40%) (Figure 4B).  In contrast, there was no significant difference in 
systemic arterial pressure among the groups in the prevention or treatment protocols (Figure 4C 
and 4D).   
 
Combination Therapy Ameliorates Right Ventricular Hypertrophy 
Right ventricular hypertrophy (RVH) is a characteristic of PH.  I confirmed a significant 
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development of RVH in the MCT group compared with the control group both in the prevention 
and treatment protocols (Figure 5).  In the prevention protocol, the monotherapy with fasudil or 
sildenafil significantly inhibited the development of RVH (by 27% and 34% respectively), which 
was further inhibited by their combination therapy (by 45%) (Figure 5A and 5C).  Also, in the 
treatment protocol, the monotherapy with fasudil or sildenafil ameliorated the developed RVH 
(by 40% and 50% respectively), which was further inhibited by their combination therapy (by 
61%) (Figure 5B and 5D). 
 
Combination Therapy Ameliorates Pulmonary Vascular Remodeling 
During PH, remodeling of pulmonary vasculatures occurs especially in the medial wall.  So, the 
medial wall thickening of the pulmonary arteries after the drug treatment was evaluated.  
Histological examination from the prevention protocol showed that medial wall thickening of the 
pulmonary arteries was reduced in the combination group compared with other groups (Figure 
6A).  Quantitative analysis of the pulmonary arteries demonstrated that MCT caused a 
significant increase in the medial wall thickness of the pulmonary arteries (Figure 6B and 6C).  
In contrast, the monotherapy with fasudil or sildenafil significantly ameliorated the development 
of medial wall thickening, which was further ameliorated by their combination therapy (Figure 
6B and 6C).      
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Combination Therapy Ameliorates RV Function and Long-term Survival 
Echocardiographic examination in the prevention protocol showed that RV dilatation, as 
evaluated by RV end-diastolic (EDD) and end-systolic dimension (ESD), was developed together 
with reduced RV fractional shortening (RVFS) in the MCT group compared with the control 
group (Figure 7A to 7D).  Those MCT-induced changes were improved by the monotherapy 
with fasudil or sildenafil, and further improved by their combination therapy (Figure 7A to 7D).   
Survival study showed the beneficial effects of long term combination therapy with 
fasudil and sildenafil over the monotherapy with either fasudil or sildenafil.  In the prevention 
protocol, no animals died during the 3 weeks of follow-up period in the MCT group.  In contrast, 
in the treatment protocol, 79% of the animals died by 9 weeks in the MCT group (Figure 8).  I 
noted pleural effusion in the dead animals, indicating that the potential cause of death was RV 
failure.  Importantly, the monotherapy with fasudil or sildenafil significantly improved the 
survival rate (46% and 58% respectively), which was further improved by the combination 
therapy (78%) in the treatment protocol (Figure 8).  I also measured body weight, food and 
water intakes that may be related to their longevity.  Body weight was significantly reduced in 
the MCT group and the treatment groups compared with the control group in both the prevention 
(Figure 9A) and treatment protocols (Figure 10A).  Similarly, the amount of water and food 
intakes was significantly reduced in the MCT group and the treatment groups compared with the 
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control group in both the prevention (Figure 9B and 9C) and treatment protocols (Figure 10B 
and 10C).  Additionally, combination therapy with fasudil and sildenafil significantly reduced 
the lung weight in the treatment protocol by restoring the adverse changes in the lung structure 
associated with monocrotaline-induced PH (Figures 11A and 11B). 
 
Combination Therapy Inhibits Rho-kinase Activity 
To elucidate the mechanism involved in the significant improvement of PH, RV function and 
survival in the combination group, I performed Western blot analysis to quantify Rho-kinase 
activity in tissues from PA trunk, lung, and RV in the prevention protocol.  The MCT group 
showed significant increase in Rho-kinase activity in the PA trunk compared with the control 
group (Figure 12A and 12B).  In contrast, monotherapy with fasudil or sildenafil significantly 
inhibited the Rho-kinase activity in the PA trunk, which was further inhibited by their 
combination therapy (Figure 12B).  Additionally, the monotherapy with fasudil or sildenafil 
showed marked inhibition of Rho-kinase activity in the lung and RV tissue, with no further 
inhibition by their combination therapy (Figure 12C and 12D).   
ERK1/2 signaling plays an important role in the regulation of VSMC proliferation and 
pulmonary vascular remodeling.52)  Thus, I performed Western blot analysis to measure ERK1/2 
activity in the tissues from PA trunk and lung.  The MCT group showed significant increase in 
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the ERK1/2 activity compared with the control group (Figure 13A and 13B).  In contrast, the 
monotherapy with fasudil or sildenafil significantly attenuated the ERK activity, which was 
further inhibited by the combination therapy in the lung but not in the PA (Figure 13A and 13B). 
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Discussion 
 
The major finding of the present study is that the combination therapy with fasudil and sildenafil 
has a significant efficacy in the treatment of MCT-induced PH in rats.  In the present study, I 
performed 2 protocols to examine the efficacy of the combination therapy, which showed 
significant effects over the monotherapy by improving RVSP, RVH and pulmonary vascular 
remodeling.  Importantly, the combination therapy significantly improved RV functions and 
long-term survival through Rho-kinase inhibition.  
 
Combination Therapy Ameliorates Pulmonary Vascular Remodeling 
MCT is known to cause endothelial injury of pulmonary arteries with subsequent proliferation of 
pulmonary VSMC, infiltration of inflammatory cells and pulmonary vascular remodeling.20)  
Rho-kinase plays an important role in mediating various cellular functions, including VSMC 
contraction, actin cytoskeleton organization,25) and cytokinesis,29) thereby developing 
cardiovascular diseases.27)  Importantly, Rho-kinase is substantially involved in the vascular 
effects of various vasoactive factors.27) Rho-kinase inhibitors have an inhibitory effect on 
proliferation and migration of VSMC and infiltration of inflammatory cells.29)  It has also been 
shown that statins enhance eNOS mRNA stability by cholesterol-independent mechanisms 
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involving the inhibition of Rho geranyl-geranylation.53)  Importantly, Rho-kinase inhibitors 
induce vasodilation especially where vasoconstrictor tone is increased by a variety of 
mechanisms including hypoxia, NOS inhibition and other mechanisms.54)  In contrast, sildenafil 
inhibits pulmonary vascular remodeling by different mechanism targeting the endothelial NO 
synthase (eNOS)-NO-cGMP pathway.55)  Thus, Rho-kinase inhibition and PDE5 inhibition may 
have additive and synergistic effects in terms of vascular dilatation and remodeling (Figure 14).  
Indeed, in the present study, the combination therapy with fasudil and sildenafil significantly 
ameliorated MCT-induced pulmonary vascular remodeling.   
 
Combination Therapy Improves RV Function and Survival  
PH causes RV failure, characterized by increased RV pressure and reduced RV fractional 
shortening, and ultimately premature death.56)  Fasudil suppresses Rho-kinase-mediated 
vasoconstriction by dephosphorylation of myosin phosphatase in pulmonary arteries of rats.57)  
In addition, sildenafil increases cGMP level through PDE5 inhibition and causes vasodilation of 
pulmonary arteries in rats.17)  In severe PH, increased pulmonary vascular resistance causes RV 
pressure overload and develops imbalance between RV oxygen demand and supply, resulting in 
RV failure.  RV dysfunction is also augmented by LV dysfunction due to myocardial ischemia 
and by interventricular interaction through the ventricular septal wall.58)  These changes in RV 
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dysfunction are associated with multiple cellular changes, such as oxidative stress, apoptosis, 
inflammation, fibrosis and metabolic remodeling.59, 60)  Importantly, Rho-kinase activity is 
increased in most of the cardiovascular diseases, including myocardial ischemia and 
remodeling.61)  Rho-kinase inhibition by fasudil protects cardiovascular tissues by activating 
phosphatidylinositol 3-kinase/protein kinase Akt/eNOS pathway that has anti-apoptotic and 
anti-inflammatory effects and by decreasing the ventricular tachycardia.62-64)  In contrast, PDE5 
is strongly expressed in vascular beds and cardiac myocytes, which blocks NO-mediated cGMP 
generation.65)  Importantly, sildenafil exerts cardioprotective effects by increasing NO generated 
by eNOS or iNOS, thereby opening of mitochondrial ATP-sensitive potassium channels or by 
decreasing the ventricular arrhythmia.66-68)  In the present study, I was able to demonstrate that 
the combination therapy with fasudil and sildenafil significantly improved RV function and 
long-term survival compared with each monotherapy (Figure 14).   
 
Additive and Synergistic Effects by the Combination Therapy 
Rho-kinase plays an important role in the pathogenesis of PH directly by activating its substrates 
and indirectly by mediating the signal transduction of various inflammatory mediators.27, 38)  In 
contrast, the NO/cGMP pathway plays crucial roles in vasoconstriction and pulmonary vascular 
remodeling.34, 42, 69)  Importantly, this pathway is closely associated with the Rho/Rho-kinase 
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system by regulating cGMP-dependent phosphorylation of RhoA in VSMC.70)  Indeed, it has 
been shown that Rho-kinase inhibitors increase vascular eNOS expression and exert 
cGMP-mediated vasodilatation.62, 71, 72)  Thus, fasudil blocks vasoconstriction through 
dephosporylation of myosin phosphatase57) and sildenafil causes relaxation by cGMP-dependent 
mechanism.48)  Consistently, I demonstrated a significant inhibition of Rho-kinase-mediated 
MYPT phosphorylation by combination therapy with fasudil and sildenafil.   
It was previously demonstrated that the NO/cGMP pathway regulates RhoA by 
phosphorylating them by cGMP-dependent protein kinase (PKG).48, 70)  This phosphorylation 
prevents the translocation of active GTP-bound RhoA to the membrane, resulting in the inhibition 
of Rho-kinase activity.48, 70)  Thus, sildenafil activates the NO/cGMP pathway and thereby 
inhibits the RhoA/Rho-kinase pathway.  So, fasudil inhibits Rho-kinase directly through 
dephosphorylation of myosin phosphatase.57)  In contrast, sildenafil inhibits Rho-kinase 
indirectly through the cGMP-dependent protein kinase (PKG) or G-kinase.48, 70)  So, from above 
discussion, it is found that fasudil and sildenafil can synergize each other activity in terms of 
Rho-kinase and eNOS expression beyond their individual activities.  In the present study, I was 
able to demonstrate a significant inhibition of Rho-kinase activity in the PA by the combination 
therapy compared with each monotherapy.  Thus, I propose additive and synergistic Rho-kinase 
inhibition by the combination therapy with fasudil and sildenafil (Figure 14).  
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 Previous studies have demonstrated that the Ras/ERK signaling pathway regulates a 
variety of processes including VSMC proliferation52) and pulmonary vascular remodeling.73)  In 
the present study, I observed ERK1/2 activation in the MCT-treated rats.  The phosphorylated 
ERK1/2 needs to be translocated to the nucleus for many of its action.  Recently, it has been 
demonstrated that the nuclear translocation of phosphorylated ERK1/2 depends on the 
Rho-kinase activity.74)  Fasudil inhibits VSMC proliferation by blocking the nuclear 
translocation of ERK1/2.75)  All of these reports support our present finding that the treatment 
with fasudil inhibited phosphorylation of Rho-kinase and ERK1/2.  In contrast, sildenafil 
inhibits VSMC proliferation through activating the cGMP/PKG pathway, where cGMP activates 
PKG to induce the mitogen activated protein kinase phosphatase-1 (MKP-1) enzyme that 
deactivates ERK1/2.76, 77)  In the present study, I was able to demonstrate that sildenafil reduced 
ERK1/2 activity in both the PA trunk and lung.  Taken together, the combination therapy with 
fasudil and sildenafil significantly inhibits ERK1/2 activity and Rho-kinase activity compared 
with each monotherapy (Figure 14). 
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Study Limitations  
 
Several limitations should be mentioned for the present study.  First, MCT-induced PH model 
may not fully represent PH in humans and thus the effectiveness of the combination therapy 
should be evaluated in other PH models with different etiologies.  Second, the relatively high 
doses of fasudil and sildenafil were used in the present model of MCT-induced PH model in rats.  
Thus, it remains to be examined whether the combination therapy of clinical doses of fasudil and 
sildenafil also exerts further beneficial effects on PH.  Third, I was unable to measure plasma 
concentration of fasudil and sildenafil due to technical difficulty. 
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Conclusions 
 
In conclusions, the combination therapy with fasudil and sildenafil significantly improves 
pulmonary vascular remodeling, RV dysfunction, and survival in MCT-induced PH in rats.   
PH continues to be a serious disease with high mortality.  In spite of the recent progress in 
understanding of PH pathogenesis and development of new drugs, I remain to have satisfactory 
treatment in patients with PH.  Further experimental and clinical studies are necessary. 
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Figure Legends 
 
Figure 1.  Pathogenesis of Pulmonary Arterial Hypertension (PAH) 
(A) The pathogenesis of PAH is shown.  Abnormalities can be seen at each level of the small 
pulmonary arteries, beginning in the blood and traveling outward to the adventitia.    (B) 
Current therapies in PAH are based on these three major pathways which are involved in 
abnormal proliferation and contraction of the smooth muscle cells of the pulmonary artery.  
These pathways correspond to important therapeutic targets as endothelin-receptor antagonists, 
phosphodiesterase type 5 inhibitors, and prostacyclin derivatives.   SOD2, superoxide 
dismutase 2; ET-1, endothelin-1; TxA2, thromboxane A2; BNP, brain natriuretic peptide; PGl2, 
prostacylin; 5-HTT, 5-hydroxy-tryptamine; and MMP, matrix metalloproteinase; cGMP, cyclic 
guanosine monophosphate; cAMP, cyclic adenosine monophosphate.  
 
Figure 2.  Role of Rho-kinase and NO/cGMP/PDE5 pathway in PAH 
(A) Schematic illustration of pathophysiological components contributing to the development of 
pulmonary hypertension.  Rho-kinase activation may be involved in the pathological changes of 
pulmonary arteries.  (B) The diagram describes the molecular pathway that controls NO activity 
and VSMC relaxation.  Once inside the smooth muscle cell, NO binds to the iron core of soluble 
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guanylyl cyclase enabling faster conversion of GTP into cGMP.  But PDE5 causes hydrolysis of 
cGMP and causes vascular remodeling.  NO, nitric oxide; VSMC, vascular smooth muscle cell; 
PVR, pulmonary vascular resistance; PAP, pulmonary arterial pressure; GTP, guanosine 
triphosphate; cGMP cyclic guanosine monophosphate; PDE5, phosphodiesterase type 5. 
 
Figure 3.  Experimental protocols 
Male rats were divided into 5 groups, including control (CTR), MCT (MCT), fasudil (FAS), 
sildenafil (SIL), and combination of fasudil and sildenafil (FAS+SIL) groups.  To induce 
pulmonary hypertension, all rats except the CTR group received a subcutaneous injection of 
MCT and the CTR group that of saline at day 0.  (A) In the prevention protocol, drugs and 
vehicle (for the CTR group) were administered every day.  After 3 weeks, the animals were 
used for analyses.  (B) In the treatment protocol, administration of drugs or vehicle was started 
after 3 weeks of MCT injection.  After 9 weeks, the animals were used for analyses. 
 
Figure 4.  Combination therapy improves hemodynamic variables  
(A, B) Compared with the control (CTR) group, right ventricular systolic pressure (RVSP) was 
elevated in the monocrotaline (MCT) group.  The combination therapy significantly attenuated 
the MCT-induced increase in RVSP compared with each monotherapy in both the prevention (A) 
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and treatment (B) protocols.  (C, D) MCT did not affect systolic arterial pressure (SAP) in any 
groups in the prevention or treatment protocol.  Results are expressed as mean ± SEM.  
Animals used in the prevention protocol as CTR (n=10); MCT (n=9); FAS (n=8); SIL (n=9); 
FAS+SIL (n=9) and in the treatment protocol as CTR (n=8); MCT (n=6); FAS (n=6); SIL (n=8); 
FAS+SIL (n=8).  **P < 0.01, ***P<0.001. 
 
Figure 5.  Effects of combination therapy on right ventricular hypertrophy 
(A to D) The ratio of right ventricle to left ventricle plus septum weight [RV/(LV+Sep)] and the 
ratio of right ventricle to body weight (RV/BW) were increased in the monocrotaline (MCT) 
group compared with the control (CTR) group.  The combination therapy significantly 
attenuated the development of right ventricular hypertrophy compared with the monotherapy.  
Results are expressed as mean ± SEM.  Animals used in the prevention protocol as CTR (n=10); 
MCT (n=10); FAS (n=9); SIL (n=10); FAS+SIL (n=9) and in treatment protocol as CTR (n=6); 
MCT (n=5); FAS (n=6); SIL (n=6); FAS+SIL (n=6).  *P<0.05, **P<0.01, ***P<0.001. 
 
Figure 6.  Inhibitory effects of the combination therapy on pulmonary microvascular 
remodeling 
(A) Representative photomicrographs showing macroscopic features of pulmonary arteries by 
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Elastica-Masson staining. Scale bars, 50 μm.  (B, C) Quantitative analysis of medial wall 
thickness of pulmonary arteries.  Compared with the control (CTR) group, medial thickness of 
pulmonary arteries was markedly increased in the monocrotaline (MCT) group.  The 
combination therapy significantly attenuated the development of medial wall thickening 
compared with each monotherapy.  Results are expressed as mean ± SEM (n = 5 each group).  
*P<0.05, **P<0.01, ***P<0.001. 
 
Figure 7.  Effects of the combination therapy on RV function 
(A) Representative echocardiographic images of the right ventricle (RV).  Vertical yellow bar 
shows RV enddiastolic diameter (RVEDD) and vertical blue bar RV endsystolic diameter 
(RVESD).  (B, C) RVEDD and RVESD Ire markedly increased in the monocrotaline (MCT) 
group compared with the control (CTR) group.  The combination therapy significantly reduced 
RVEDD and RVESD compared with each monotherapy.  (D) RV contractility assessed by RV 
fractional shortening (RVFS) was significantly reduced in the monocrotaline (MCT) group 
compared with the CTR group, and was significantly improved by the combination therapy 
compared with the monotherapy. Results are expressed as mean ± SEM.  Animals used here as 
CTR (n=4); MCT (n=3); FAS (n=5); SIL (n=5); FAS+SIL (n=5).  *P<0.05, **P<0.01, 
***P<0.001. 
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Figure 8.  The combination therapy improves the survival 
The Kaplan-Meier curve shows that the combination therapy improved long-term survival 
compared with the monotherapy.  Control group (CTR, n = 12); monocrotaline group (MCT, n = 
39); fasudil group (FAS, n = 26); sildenafil group (SIL, n = 24); and combination group 
(FAS+SIL, n = 27).  *log-rank P<0.05, **log-rank P<0.01, ***log-rank P<0.001. 
 
Figure 9.  Time-course of body weight (BW) and intakes of food and water in the 
prevention protocol 
Time-courses of body weight (BW) (A), water intake (B) and food consumption (C) are shown.  
BW, water intake and food consumption were significantly reduced in the MCT group and the 
treatment groups compared with the CTR group.  Results are expressed as mean ± SEM (n = 15 
each group).  *P<0.05, **P<0.01. 
 
Figure 10.  Time-courses of body weight (BW) and intakes of food and water in the 
treatment protocol 
Time-courses of body weight (BW) (A), water intake (B) and food consumption (C) are shown.  
BW, water intake and food consumption were significantly reduced in the MCT group and the 
treatment groups compared with the CTR group.  Results are expressed as mean ± SEM.  
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Animals used here as CTR (n=6); MCT (n=5); FAS (n=6); SIL (n=6); FAS+SIL (n=6).  
*P<0.05, ***P<0.001. 
 
Figure 11.  Effects of combination therapy on lung weight of rat in treatment protocol. 
Lung weight (A) and ratio of lung weight to body weight (B) were significantly increased in the 
MCT group compared with the CTR group.  However combination therapy significantly 
reduced the gained lung weight compared with monotherapy.  Results are expressed as mean ± 
SEM.  Animals used here as CTR (n=6); MCT (n=5); FAS (n=5); SIL (n=6); FAS+SIL (n=6).  
*P<0.05, **P<0.01, ***P<0.001. 
 
Figure 12.  The inhibitory effects of the combination therapy on Rho-kinase activity 
The combination therapy significantly inhibits monocrotaline (MCT)-induced Rho-kinase 
activation.  (A) Rho-kinase activity was assessed by the ratio of phosphorylated MYPT 
(pMYPT) per total MYPT (tMYPT).  (B to D) Rho-kinase activity (pMYPT/tMYPT) is shown 
by bar graphs and expressed as the ratio relative to the control group (CTR).  Results are 
expressed as mean ± SEM (n = 5 each group).  *P<0.05, **P<0.01, ***P<0.001. 
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 Figure 13.  The inhibitory effects of the combination therapy on ERK activity 
The combination therapy significantly inhibited monocrotaline (MCT)-induced ERK activation.  
ERK activities in pulmonary arteries and lung were assessed by the ratio of phosphorylated 
ERK1/2 (pERK) per total ERK1/2 (tERK).  (A, B) ERK activities (pERK/tERK) are shown by 
bar graphs and expressed as the ratio relative to the control group (CTR).  Results are expressed 
as mean ± SEM (n = 5 each group). *P<0.05, **P<0.01, ***P<0.001. 
 
Figure 14.  Additive and synergistic effects of the combination therapy 
Additive and synergistic effects through Rho-kinase inhibition by the combination therapy with 
fasudil and sildenafil.  5-HT, serotonin; AC, adenylate cyclase; CaM, calmodulin; ET-1, 
endothelin 1; eNOS, endothelial nitric oxide synthase; GC, guanylate cyclase; GPCR, G-protein 
coupled receptor; IP3, inositol 1,4,5-triphosphate; MLCK, myosin light chain kinase; MLCPh, 
myosin light chain phosphatase; NO, nitric oxide; PDE-5, phosphodiesterase-5; VSMC, vascular 
smooth muscle cell; PLC, phospholipase C; SR, sarcoplasmic reticulum; TXA2, thromboxane A2. 
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